Covered recipient · General Payments record
EDWARD SOMMA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$4,097.95
- Reported across 237 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $261.53 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $92.63 | 6 |
| Lilly USA, LLC | $61.33 | 4 |
| SANOFI-AVENTIS U.S. LLC | $30.54 | 2 |
| Acerta Pharma LLC | $28.58 | 2 |
| Phadia US Inc. | $16.36 | 1 |
| Novo Nordisk AS | $16.10 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $15.99 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.11 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117387920 | CMS |
| Amgen Inc. | $16.39 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117387922 | CMS |
| Amgen Inc. | $14.50 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111713072 | CMS |
| Amgen Inc. | $16.01 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111713074 | CMS |
| Amgen Inc. | $15.38 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111713076 | CMS |
| Amgen Inc. | $15.24 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111713078 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.39 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105384155 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.19 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104765630 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $15.99 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086259866 | CMS |
| Lilly USA, LLC | $14.06 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136148274 | CMS |
| Lilly USA, LLC | $14.69 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136158029 | CMS |
| Lilly USA, LLC | $16.25 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136154746 | CMS |
| Lilly USA, LLC | $16.33 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136166298 | CMS |
| Novo Nordisk Inc | $16.10 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096651532 | CMS |
| Phadia US Inc. | $16.36 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1067578258 | CMS |
| SANOFI-AVENTIS U.S. LLC | $16.50 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139596051 | CMS |
| SANOFI-AVENTIS U.S. LLC | $14.04 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139596141 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.